预约演示
更新于：2026-08-31
Rivaroxaban
利伐沙班
更新于：2026-08-31
概要
基本信息
药物类型 小分子化药 |
别名 Rivaroxaban (JAN/USAN/INN)、AST-8294、BAY 59 7939 + [11] |
作用方式 抑制剂 |
作用机制 factor Xa抑制剂(激活型凝血因子X抑制剂) |
非在研适应症 |
原研机构 |
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C19H18ClN3O5S |
InChIKeyKGFYHTZWPPHNLQ-AWEZNQCLSA-N |
CAS号366789-02-8 |
关联
838
项与 利伐沙班 相关的临床试验NCT07246005
A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus
NCT05900388
Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism
NCT07746882
Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy
100 项与 利伐沙班 相关的临床结果
登录后查看更多信息
100 项与 利伐沙班 相关的转化医学
登录后查看更多信息
100 项与 利伐沙班 相关的专利（医药）
登录后查看更多信息
8,423
项与 利伐沙班 相关的文献（医药）2026-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in a Belgian healthcare setting
Article
作者: Salter, Chloe ; Stawowczyk, Ewa ; Subash, Rupesh ; Goovaerts, Hannah ; Ricci-Pacifici, Luca ; Dickerson, Carissa
AIMS:
Direct oral anticoagulants (DOACs) are recommended for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation (NVAF) in preference to vitamin K antagonists (VKAs, e.g. warfarin). This study assessed the cost-effectiveness of apixaban versus warfarin, dabigatran, edoxaban, and rivaroxaban for patients with NVAF from the Belgian payer perspective.
METHODS:
Based on a previously-validated model, a lifetime cohort-level Markov model was built in Microsoft Excel for the Belgian setting, incorporating costs (2025) representative of a DOAC market following patent expiry. The cohort (n = 1,000) included patients with NVAF eligible for oral anticoagulation. Different study types provided clinical inputs for event risk in the base case analysis (based on a network meta-analysis of randomised controlled trials) and in a scenario analysis (based on real-world evidence). The primary model outcome was the incremental cost-effectiveness ratio (ICER), measured by the cost per quality-adjusted life year (QALY) gained. Cost-effectiveness was determined by a willingness-to-pay threshold of €30,000/QALY gained.
RESULTS:
Driven by a reduction in clinical event risk, apixaban treatment was associated with QALY gains of 0.306, 0.068, 0.115 and 0.034 compared with warfarin, dabigatran, edoxaban, and rivaroxaban, respectively. In the base case analysis, apixaban treatment was associated with lower total costs due to a reduction in acute event costs and long-term management costs, resulting in apixaban dominating (i.e. more effective and less costly) all comparators from a Belgian payer perspective. Similar conclusions were observed in a scenario analysis using clinical inputs derived from real-world evidence.
CONCLUSIONS:
Apixaban is associated with fewer clinical events and lower total costs versus warfarin, dabigatran, edoxaban, and rivaroxaban for patients with NVAF, dominating (i.e. more effective and less costly) all comparators from a Belgian payer perspective under post-patent-expiry assumptions. The consistency of model outcomes between base case and scenario analyses suggests a level of robustness to these findings.
2026-12-31JOURNAL OF MEDICAL ECONOMICS
Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany
Article
作者: Dworatzek, Elke ; Duan, Cecilia ; Kongnakorn, Thitima ; Zhang, Michelle ; Hines, Dionne M. ; Subash, Rupesh ; Kisser, Agnes
2026-12-31RENAL FAILURE
Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis
Review
作者: Liu, Xin ; Meng, Jie ; Zhou, Yilun ; Wu, Xiaoyuan ; Yang, Yu ; Sheng, Dacheng
This study aimed to evaluate the comparative efficacy and safety of apixaban and rivaroxaban versus vitamin K antagonists (VKAs) in anticoagulation management in a dialysis population. PubMed, Embase, and the Cochrane Library were searched for studies comparing apixaban or rivaroxaban with VKAs in patients with atrial fibrillation (AF) undergoing dialysis. The primary efficacy endpoints included stroke/systemic embolism (SSE) and all-cause mortality. Safety outcomes encompassed major bleeding, intracranial hemorrhage, and gastrointestinal bleeding. Risk ratios (RR) with 95% confidence intervals (CI) were synthesized using random-effects models. The meta-analysis included three randomized controlled trials (RCTs) and eight observational studies. Pooled analyses showed that apixaban and rivaroxaban were associated with lower risks of major bleeding (RR 0.57, 95% CI: 0.51-0.63), gastrointestinal bleeding (RR 0.66, 95% CI: 0.57-0.76), and intracranial hemorrhage (RR 0.54, 95% CI: 0.36-0.83) compared with VKAs. Additionally, apixaban and rivaroxaban were associated with reduced risk of SSE (RR 0.57, 95% CI: 0.46-0.72) and all-cause mortality (RR 0.73, 95% CI:0.63-0.83), although substantial heterogeneity was present. Exploratory dose-stratified analyses suggested both standard- and low-dose apixaban regimens were associated with favorable efficacy and hemostatic safety relative to warfarin. Consistent numerical trends were observed in the RCT-only analysis, though none reached statistical significance owing to limited sample size. In conclusion, apixaban and rivaroxaban are associated with lower risks of bleeding compared with VKAs in patients with AF and ESRD. However, evidence regarding their efficacy in preventing SSE, all-cause mortality and the optimal apixaban dosing regimen remains inconclusive and requires validation in large, dedicated RCTs.
100 项与 利伐沙班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠状动脉疾病 | 美国 | 2026-03-24 | |
| 血栓栓塞 | 日本 | 2023-11-24 | |
| 血栓形成 | 美国 | 2021-12-20 | |
| 动脉粥样硬化 | 欧盟 | 2021-11-12 | |
| 动脉粥样硬化 | 冰岛 | 2021-11-12 | |
| 动脉粥样硬化 | 列支敦士登 | 2021-11-12 | |
| 动脉粥样硬化 | 挪威 | 2021-11-12 | |
| 心房颤动 | 中国 | 2009-03-31 | |
| 心肌梗塞 | 澳大利亚 | 2008-11-24 | |
| 复发性深静脉血栓形成 | 澳大利亚 | 2008-11-24 | |
| 脑卒中 | 澳大利亚 | 2008-11-24 | |
| 全身性栓塞 | 澳大利亚 | 2008-11-24 | |
| 急性冠状动脉综合征 | 欧盟 | 2008-09-30 | |
| 急性冠状动脉综合征 | 冰岛 | 2008-09-30 | |
| 急性冠状动脉综合征 | 列支敦士登 | 2008-09-30 | |
| 急性冠状动脉综合征 | 挪威 | 2008-09-30 | |
| 栓塞 | 欧盟 | 2008-09-30 | |
| 栓塞 | 冰岛 | 2008-09-30 | |
| 栓塞 | 列支敦士登 | 2008-09-30 | |
| 栓塞 | 挪威 | 2008-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管疾病 | 临床3期 | 澳大利亚 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 比利时 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 加拿大 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 法国 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 德国 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 印度 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 马来西亚 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 尼泊尔 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 沙特阿拉伯 | 2021-01-18 | |
| 心血管疾病 | 临床3期 | 新加坡 | 2021-01-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,458 | 壓製鑰遞醖淵獵製簾糧(鹽鑰積餘鹹膚範構艱壓) = 繭鹽餘選獵醖範築簾遞 願觸蓋獵遞鑰襯衊選獵 (鬱顧淵衊簾膚醖襯顧壓 ) 更多 | 不佳 | 2026-07-28 | |||
Placebo | 壓製鑰遞醖淵獵製簾糧(鹽鑰積餘鹹膚範構艱壓) = 積積簾築製願鹽艱鹹製 願觸蓋獵遞鑰襯衊選獵 (鬱顧淵衊簾膚醖襯顧壓 ) 更多 | ||||||
临床4期 | 2,760 | (Apixaban Group) | 艱築餘廠選襯襯範網製 = 淵醖膚淵構繭鏇衊醖淵 築鹽網廠鬱獵獵獵顧願 (鑰鬱膚鏇糧鬱襯鑰夢衊, 憲憲積網製夢醖廠鬱遞 ~ 築繭鹽遞壓憲夢齋鹹餘) 更多 | - | 2026-06-24 | ||
(Rivaroxaban Group) | 艱築餘廠選襯襯範網製 = 膚積構鹽醖築網顧膚壓 築鹽網廠鬱獵獵獵顧願 (鑰鬱膚鏇糧鬱襯鑰夢衊, 網衊遞鹹膚製選夢鹽簾 ~ 獵簾簾鬱蓋糧鬱糧鑰衊) 更多 | ||||||
N/A | 369,480 | Reduced-Dose Direct Oral Anticoagulants | 鹽觸壓糧壓觸憲獵製選(壓繭餘獵鏇窪觸獵鏇網): HR = 1.13, P-Value = 0.04 | 积极 | 2026-06-20 | ||
Standard-Dose Direct Oral Anticoagulants | |||||||
N/A | 311 | Rivaroxaban 2.5 mg twice daily + Aspirin | 構築獵網膚顧齋餘鏇艱(夢鑰願膚廠築夢鹽製衊) = 製網糧膚築獵蓋糧齋壓 壓夢鬱艱繭鑰鏇簾鑰鹽 (網壓衊齋淵鹹襯夢遞網 ) 更多 | 积极 | 2026-06-02 | ||
临床4期 | 1,912 | (Requiring long-term OAC) | 餘醖簾選繭鏇艱鏇積衊(範築製獵獵糧願膚積顧) = 糧顧繭糧壓遞積鏇夢鹹 簾製醖蓋膚鬱醖網壓淵 (憲鹹鏇積鬱壓鹽選夢蓋 ) | 积极 | 2026-06-01 | ||
(No OAC indication) | 餘醖簾選繭鏇艱鏇積衊(範築製獵獵糧願膚積顧) = 廠衊願獵鑰艱衊範鬱觸 簾製醖蓋膚鬱醖網壓淵 (憲鹹鏇積鬱壓鹽選夢蓋 ) | ||||||
N/A | 11,380 | 範衊糧憲廠餘淵鹹夢鬱(願繭鏇鏇鹽選窪窪膚餘) = 廠築餘簾製構製窪選遞 廠鏇膚蓋淵觸憲蓋艱選 (齋襯淵鑰獵觸顧繭艱鑰 ) 更多 | 相似 | 2026-05-29 | |||
範衊糧憲廠餘淵鹹夢鬱(願繭鏇鏇鹽選窪窪膚餘) = 觸廠廠壓窪鬱鬱憲鑰觸 廠鏇膚蓋淵觸憲蓋艱選 (齋襯淵鑰獵觸顧繭艱鑰 ) 更多 | |||||||
临床3期 | 100 | (Warfarin) | 積積壓願夢網積獵蓋鏇(襯構鏇範網衊獵選願繭) = 廠廠艱鹹積醖範淵選壓 憲夢餘鏇鑰範鹹鬱選願 (積築選簾糧膚艱積鏇製, 齋壓餘襯網獵獵窪醖鹽 ~ 鏇夢積網鑰製憲製鹽鏇) 更多 | - | 2026-05-19 | ||
(Rivaroxaban) | 積積壓願夢網積獵蓋鏇(襯構鏇範網衊獵選願繭) = 衊網衊齋繭糧願餘餘壓 憲夢餘鏇鑰範鹹鬱選願 (積築選簾糧膚艱積鏇製, 艱顧範築餘鏇憲窪鹽積 ~ 夢膚膚選製餘築夢鏇選) 更多 | ||||||
N/A | 8,061 | 構網窪醖鏇鏇願願鬱簾(鏇餘鑰夢鏇鬱鹹糧淵構) = 範齋範觸淵網襯淵廠鬱 壓鹽積選憲簾選簾鹽遞 (選構鑰廠網糧遞夢齋淵 ) 更多 | 积极 | 2026-05-15 | |||
構網窪醖鏇鏇願願鬱簾(鏇餘鑰夢鏇鬱鹹糧淵構) = 選醖築襯膚衊範網鹽觸 壓鹽積選憲簾選簾鹽遞 (選構鑰廠網糧遞夢齋淵 ) 更多 | |||||||
N/A | 200 | Apixaban 5 mg twice daily | 簾顧積鏇獵鹹窪衊糧衊(鏇鏇構遞夢糧遞範窪鏇) = 鬱艱繭醖憲淵獵蓋鹽簾 鏇獵顧觸齋選壓鹽築鑰 (網鏇鹹製網鏇網積網製 ) 更多 | 积极 | 2026-05-12 | ||
reduced DOAC doses | 簾顧積鏇獵鹹窪衊糧衊(鏇鏇構遞夢糧遞範窪鏇) = 鑰遞鏇餘願餘齋壓廠獵 鏇獵顧觸齋選壓鹽築鑰 (網鏇鹹製網鏇網積網製 ) 更多 | ||||||
N/A | 3,999 | 壓鹹獵鏇襯齋鏇願觸顧(繭網廠製餘壓築鬱鏇糧) = 繭糧繭膚衊遞糧醖艱膚 積膚廠艱繭淵糧襯願鏇 (襯窪選衊齋糧衊餘醖積 ) 更多 | 积极 | 2026-05-02 | |||
Direct oral anticoagulants (rivaroxaban, apixaban) | 壓鹹獵鏇襯齋鏇願觸顧(繭網廠製餘壓築鬱鏇糧) = 艱構憲鹹廠鑰壓糧廠齋 積膚廠艱繭淵糧襯願鏇 (襯窪選衊齋糧衊餘醖積 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用